From lab to life: Advances in tissue engineering and 3D bioprinting for regenerative female reproductive health.
Tabatabai TS., Alizadeh M., Rezakhani L., Kebria MM., Mikaeili A., Gharedaghi S.
Narrative Review, published in Tissue Cell (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Tissue Cell (2026)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42385605
- DOI
- 10.1016/j.tice.2026.103736
Abstract (original English)
Infertility affects millions of women worldwide, and despite current treatment options, definitive therapies remain limited. Emerging regenerative medicine strategies, particularly stem cell therapy and three-dimensional (3D) bioprinting, offer significant potential to repair and regenerate female reproductive tissues. In this scoping review, 199 studies, including in vitro experiments, animal models, and early-stage clinical investigations, were analyzed to evaluate scientific advancements and translational potential in female reproductive tissue engineering. The focus was on stem cell sources, the development of bioinks, and the applications of 3D bioprinting to reconstruct the endometrium, ovary, cervix, and vagina. Stem cells derived from bone marrow, adipose tissue, and menstrual blood improved ovarian function and endometrial regeneration, with several animal studies reporting successful pregnancies. Concurrently, 3D bioprinting technologies enabled the creation of cell-laden scaffolds with promising potential for tissue reconstruction. Remaining challenges include the development of biocompatible bioinks, formation of functional vascular networks, and accurate recreation of extracellular matrix microenvironments. Most current approaches remain at the preclinical stage; however, the growing body of experimental evidence and early clinical investigations indicate promising
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.